Company Profile

CAPLIN POINT LABORATORIES LTD.

NSE : CAPLIPOINTBSE : 524742ISIN CODE : INE475E01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE404.25-0.35 (-0.09 % )
PREV CLOSE (Rs.) 404.60
OPEN PRICE (Rs.) 408.00
BID PRICE (QTY) 405.00 (5 )
OFFER PRICE (QTY) 407.85 (41 )
VOLUME 432
TODAY'S LOW / HIGH (Rs.)404.25 410.90
52 WK LOW / HIGH (Rs.)304.75 622.55
NSE405.50 -0.6 (-0.15 % )
PREV CLOSE(Rs.) 406.10
OPEN PRICE (Rs.) 414.00
BID PRICE (QTY) 405.05 (20 )
OFFER PRICE (QTY) 405.50 (1 )
VOLUME 4361
TODAY'S LOW / HIGH(Rs.) 405.00 414.00
52 WK LOW / HIGH (Rs.)296.05 623

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 1.74636
Dividend Yield(%)
TTM EPS (Rs.)
P/E Ratio
Book Value (Rs.)
Face Value (Rs.)
MCap (Rs. in Mn)
Price/Earning (TTM)
Price/Sales (TTM)
Price/Book (MRQ)
PAT Margin (%) 23.98
ROCE (%) 58.99
Incorporation Year : 1990

Management Info :

C C Paarthipan - Chairman Sridhar Ganesan - Managing Director

Registered Office :

Address : Narbavi, No . 3,Lakshmanan Street ,T Nagar ,
Chennai,
Tamil Nadu-600017

Phone : 91-044-28156653 / 28156905

Registrar's Details : Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai
Listing : BSE, NSE, Chennai
NEWS More
22Mar03-22-2019$Caplin Point Laboratories’ arm gets USFDA’s nod for Glycopyrrolate injection Caplin Point Laboratories’

Caplin Point Laboratories’ Wholly Owned Subsidiary -- Caplin Steriles has been granted final approval by the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Glycopyrrolate injection USP, 0.2mg/ml (in 1 ml, 2 ml, 5 ml and 20 ml vial presentations), a generic therapeutic equivalent version of Robinul from West-Ward Pharmaceuticals International Limited. Glycopyrrolate is an anticholinergic drug.

According to IQVIA (IMS Health), Glycopyrrolate had US sales data of approximately $110.12 Million for the 12 month period ending December 2018. Caplin Steriles has developed and filed a total of 11 ANDAs, of which 7 are on its own (Caplin Steriles) and 4 with partners.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Laboratories’ Wholly Owned Subsidiary -- Caplin..
22Mar03-22-2019$Caplin Point Laboratories’ inches up with its arm getting USFDA’s nod for Glycopyrrolate injection Caplin Point Laboratories’

Caplin Point Laboratories is currently trading at Rs. 405.35, up by 1.85 points or 0.46% from its previous closing of Rs. 403.50 on the BSE.

The scrip opened at Rs. 408.40 and has touched a high and low of Rs. 414.90 and Rs. 398.05 respectively. So far 30502 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 622.55 on 06-Apr-2018 and a 52 week low of Rs. 304.75 on 29-Jan-2019.

Last one week high and low of the scrip stood at Rs. 437.90 and Rs. 398.05 respectively. The current market cap of the company is Rs. 3085.71 crore.

The promoters holding in the company stood at 69.05%, while Institutions and Non-Institutions held 7.11% and 23.84% respectively.

Caplin Point Laboratories’ Wholly Owned Subsidiary -- Caplin Steriles has been granted final approval by the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Glycopyrrolate injection USP, 0.2mg/ml (in 1 ml, 2 ml, 5 ml and 20 ml vial presentations), a generic therapeutic equivalent version of Robinul from West-Ward Pharmaceuticals International Limited. Glycopyrrolate is an anticholinergic drug.

According to IQVIA (IMS Health), Glycopyrrolate had US sales data of approximately $110.12 Million for the 12 month period ending December 2018. Caplin Steriles has developed and filed a total of 11 ANDAs, of which 7 are on its own (Caplin Steriles) and 4 with partners.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Laboratories is currently trading at Rs. 405.35, u..
13Feb02-13-2019$Caplin Point Laboratories informs about allotment of equity shares Caplin Point Laboratories in

Caplin Point Laboratories has informed that the Nomination and Remuneration Committee has allotted 26,750 equity shares of Rs 2 each to the option grantee who has exercised his options. The Company will be applying for listing of the above shares with the exchanges to complete the issue formalities. With this allotment, the number of equity shares outstanding has 7,56,03,500 to 7,56,30,250 and the paid up equity capital from Rs 15,12,60,500.

The above information is a part of company’s filings submitted to BSE.

Caplin Point Laboratories has informed that the Nomination and..
31Jan01-31-2019$Caplin Point Laboratories informs about earnings conference call Caplin Point Laboratories in

Caplin Point Laboratories has informed about earnings conference call on February 11, 2019.

The above information is a part of company’s filings submitted to BSE.

Caplin Point Laboratories has informed about earnings conferenc..
18Jan01-18-2019$Caplin Point Laboratories informs about outcome of the board meeting Caplin Point Laboratories in

Caplin Point Laboratories has informed about outcome of the Board Meeting held on January 18, 2019.

The above information is a part of company’s filings submitted to BSE.

Caplin Point Laboratories has informed about outcome of the Boa..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit368.591023.11
Gross Profit 508.61 1460.53
Operating Profit 565.421651.02
Net Sales 1397.624265.74
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Piramal Enterprises (BSE)
 2616.00 (1.63%)
M.Cap ( in Cr)
48196.31
Sanofi India (BSE)
 5590.00 (0.53%)
M.Cap ( in Cr)
12874.12
Torrent Pharma (BSE)
 1881.00 (0.94%)
M.Cap ( in Cr)
31853.54
Glenmark Pharma (BSE)
 650.80 (2.29%)
M.Cap ( in Cr)
18221.01
Alkem Laboratories (BSE)
 1723.75 (0.56%)
M.Cap ( in Cr)
20610.02
Shareholding Pattern More
PROMOTERS 69.05 %
NON-INSTITUTION 23.84 %
FI/BANKS/INSURANCE 0.03 %
MUTUAL FUNDS/UTI 0 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
Scheme NameHold(%)
ICICI Pru S&P BSE 500 ETF0.01
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested